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OBJECTIVES: Chronic thromboembolic pulmonary hypertension (CTEPH) is a unique form of pulmonary
hypertension (PH) that arises from obstruction of the pulmonary vessels by recanalized thromboembolic
material. CTEPH has a wide range of radiologic presentations. Commonly, it presents as main pulmonary artery
enlargement, peripheral vascular obstructions, bronchial artery dilations, and mosaic attenuation patterns.
Nevertheless, other uncommon presentations have been described, such as lung cavities. These lesions may be
solely related to chronic lung parenchyma ischemia but may also be a consequence of concomitant chronic
infectious conditions. The objective of this study was to evaluate the different etiologies that cause lung cavities
in CTEPH patients.
METHODS: A retrospective data analysis of the medical records of CTEPH patients in a single reference PH center
that contained or mentioned lung cavities was conducted between 2013 and 2016.
RESULTS: Seven CTEPH patients with lung cavities were identified. The cavities had different sizes, locations, and
wall thicknesses. In two patients, the cavities were attributed to pulmonary infarction; in 5 patients, an
infectious etiology was identified.
CONCLUSION: Despite the possibility of being solely associated with chronic lung parenchyma ischemia, most
cases of lung cavities in CTEPH patients were associated with chronic granulomatous diseases, reinforcing the
need for active investigation of infectious agents in this setting.
KEYWORDS: Chronic Thromboembolic Pulmonary Hypertension; Lung Cavities; Pulmonary Infarction; Chronic
Granulomatous Diseases; Infection.
’ INTRODUCTION
Chronic thromboembolic pulmonary hypertension (CTEPH)
is a unique form of pulmonary hypertension (PH) that arises
from obstruction of the pulmonary vessels by organized thro-
mboembolic material (1). CTEPH has historically been shown
to be a challenging clinical entity that is frequently underdiag-
nosed and undertreated. The primary therapeutic approach
that should be implemented for CTEPH is pulmonary
endarterectomy (PEA), a surgery that removes the occluding
material from the pulmonary vessels as well as the vascular
endothelium (2), and lifelong anticoagulation (3).
CTEPH has a wide range of radiologic presentations.
Unlike acute pulmonary embolism (4-6), CTEPH frequently
presents as enlargement of the main pulmonary artery,
peripheral vascular obstructions, bronchial artery dilations,
and mosaic attenuation patterns (7). Nevertheless, other
uncommon presentations have been described, such as lung
cavities (8-11). These lesions may be solely related to chronic
lung parenchyma ischemia but may also be a consequence of
concomitant chronic infectious conditions and have signifi-
cant management implications. Herein, this study describes
seven CTEPH patients with lung cavities and discusses the
diagnostic approach and management of these conditions.
’ METHODS AND RESULTS
From 2013 to 2016, seven CTEPH patients presented lung
cavities at diagnosis in the main reference center for pulmo-
nary hypertension in Brazil (Heart Institute, SP), a country
with high endemic rates of chronic granulomatous lung
diseases. During this 4-year period, we evaluated 140 CTEPH
patients at our center and performed PEA in approximately
110 patients. These CTEPH patients mostly presented withDOI: 10.6061/clinics/2020/e1373
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symptoms similar to those of other forms of PH, progressive
dyspnea and symptoms of right ventricular failure, which
was the most prevalent presentation.
All PH patients at our center followed the diagnostic
algorithm suggested by European Society of Cardiology and
European Respiratory Society and were reviewed in 2015
(12). Therefore, during the evaluation, all PH patients under-
went a lung perfusion scan, the gold standard technique to
CTEPH confirmation (13). Once CTEPH was identified, the
patients were evaluated as possible candidates for PEA.
However, PEA is a major surgery that includes extracorpor-
eal perfusion support. Lung cavitations, in this setting, could
affect the surgical outcome since chronic infections could
be associated with these cavitations. Our decision was to
perform PEA only when the etiology of the lung cavitation in
CTEPH was clarified.
All CTEPH patients who presented lung cavitations (two
females and five males) had dyspnea at the first medical
appointment; four were considered New York Heart Asso-
ciation functional class (FC II), two were FC III, and one was
FC IV. Three patients did not present with acute PE prior to
the CTEPH diagnosis. Two patients had a background of
acute PE, and the two remaining patients had acute PE
associated with deep vein thrombosis (DVT). Regarding their
previous medical history, one patient had chronic obstructive
pulmonary disease (COPD), and another had Proteus syn-
drome (a rare congenital disorder that causes skin over-
growth and atypical bone development, often accompanied
by tumors over half the body).
All patients underwent transthoracic echocardiography
that showed a pulmonary artery systolic pressure (PASP)
greater than 40 mmHg. To characterize pulmonary hyper-
tension, the patients underwent right heart catheteriza-
tion. The clinical and hemodynamic data are described in
Table 1.
The CTEPH diagnosis was made after three months of
adequate therapeutic anticoagulation. All patients had seg-
mental perfusion defects, which were identified by a nuclear
lung perfusion scan. Thoracic computed tomography angio-
graphy (MCTA) showed pulmonary artery obstructions in all
patients. All presented lung cavities were of different sizes
and thicknesses, were surrounded by ground-glass opacities,
and were concordant with the pulmonary artery obstruction
regions. The diameter of the cavities varied from 9.4 to
25 mm, with all but one presenting a wall thickness greater
than 2 mm (Figure 1).
Table 1 - Baseline data of CTEPH patients with lung cavities.
Patients 1 2 3 4 5 6 7
Age (years) 26 42 65 28 37 24 64
Sex Male Male Male Female Female Male Male
Medical History COPD Proteus syndrome
Embolism History PE+DVT PE PE PE+DVT
Functional Class II III II IV II III II
Echocardiogram PSAP (mmHg) 60 82 69 94 112 96 70
TC6M (m) 541 214 360 262 460
BNP (pg/mL) 72 187 514 246 367 180 639
mPAP (mmHg) 63 52 42 53 64 39 53
PCWP (mmHg) 9 11 18 10 14 11 19
Cardiac Output (L/min) 5.5 4.8 4.5 3.2 3.1 4.1 2.7
Pulmonary Vascular Resistance (WOOD) 9.8 8.5 5.3 13.7 16.1 5.7 12.5
Figure 1 - Chest CT scans of 7 CTEPH patients with lung cavities. Aspects of the cavity such as wall thickness were not able to distinguish
infectious diseases from ischaemic cavities.
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The diagnostic procedure and resulting diagnosis for
each patient are described in Table 2. All but one patient with
chronic infectious diseases were successfully treated and
underwent pulmonary endarterectomy. Patients 4 and 5 died
of right ventricular failure, and the appropriate diagnosis
was only made at necropsy. No infectious agent was iden-
tified for patient 4. Patient 6 underwent a bronchoalveo-
lar lavage, but no microorganisms were detected, and the
lesion was considered purely associated with the pulmonary
infarction.
’ DISCUSSION
The study results demonstrate that, despite the possibility
of being solely associated with chronic lung parenchyma
ischemia, most cases of lung cavities in CTEPH were asso-
ciated with chronic granulomatous diseases, reinforcing
the need for active investigation of infectious agents in this
setting.
CTEPH has a variety of radiologic presentations. The most
common signs are vascular filling defects, abrupt vessel cut
off, and pulmonary parenchyma mosaic attenuation. Even-
tually, there are also findings associated with lung infarction,
such as parenchymal bands, wedge-shaped densities, and
cavities (14). Nevertheless, since the lung has dual perfusion
sources (bronchial and pulmonary circulation), even severe
vascular obstructions present in CTEPH rarely lead to
advanced necrosis and lung cavities, given that the bronchial
circulation provides some degree of perfusion. In some
clinical situations, however, the vascular balance may be
disturbed, such as in the presence of infections. Infectious
diseases increase the basal metabolic demand systemically
and locally. In this setting, the blood supply provided
exclusively by the bronchial circulation may not be enough,
and lung necrosis may occur, and a cavity may develop as a
consequence.
Lung cavities are a result of several distinct pathological
processes, such as cancer (15), suppurative necrosis (pyo-
genic lung abscess), caseous necrosis (tuberculosis) or cystic
dilation of the lung structures (16). The radiographic appea-
rance of a cavity lesion can sometimes be useful to differentiate
among a broad spectrum of etiologies but should be combined
with clinical and laboratory data for an accurate diagnosis.
One traditional method for classifying excavated lung lesions
is the use of the cavity wall thickness. Infectious diseases
usually present thick walls and may be surrounded by
micronodules on chest CTand thus, these findings frequently
favor the possibility of infection. Nevertheless, in this case
series, cavity wall thickness was not able to distinguish
infectious diseases from ischaemic cavities.
One critical condition classically associated with pulmon-
ary cavity disease is Mycobacterium tuberculosis (16). Due to
its high prevalence, the awareness of lung tuberculosis
should be high, mainly in regions with high endemic levels
for the disease. In fact, despite other potential causes for the
lung cavity, such as a vascular perfusion deficit, the majority
of these patients had some form of mycobacteria infection as
the main cause of the cavity. The adequate identification of
the etiology of the lung cavity in CTEPH may lead to a speci-
fic anti-infective therapy, when necessary, and have a direct
impact on the outcome of such a severe condition. Similarly,
nontuberculous mycobacterial lung disease was also asso-
ciated with newly formed lung cavitations in CTEPH
patients (17,18).
’ CONCLUSIONS
Lung cavities are a possible CT finding of CTEPH patients.
These cavities may be due solely to vascular impairment.
Nevertheless, an adequate evaluation of the cavity etiology is
mandatory. In most CTEPH patients with lung cavitations,
it is possible to identify an infectious agent, which may
warrant a specific anti-infective therapy approach and impact
the outcomes of severe conditions such as CTEPH.
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